Rare Genomics Institute (RG) presented at the 2015 BIO International Convention, the largest global event for the biotech industry. The event took place June 15th – 18th, in Philadelphia, Pennsylvania. It was well attended by industry experts, large pharma companies, contract research organizations, scientists, academic researchers and investigators, government and economic development agencies. It offered a chance to collaborate, and to form partnerships for the advancement of research and development. The convention attracted more than 15,000 attendees from 69 different countries.
Rare Genomics exhibited in the Pennsylvania BIO booth and was represented by Paul Schindler (CEO/Executive Director), Nolin Huddleston (Director of Strategic Alliances), and Ana Sanfilippo (VP, Global Strategy). “The opportunities to advance our mission were everywhere, people wanted to talk and build business relationships”, Mr. Schindler said. RG participated in the session on Orphan and Rare Diseases, wherein, the latest developments in therapeutic advances and drug development for rare diseases, marketing authorizations of orphan products, and, justification of the need for rare disease therapies in spite of the seemingly small patient populations were discussed. Mr. Schindler added, “Our team distributed ‘I Care for Rare’ stickers that were placed on conference badges to raise awareness for rare disease; it was great to see so many people proudly showing their support.”
Rare Genomics Institute is committed to bringing the rare disease patient to the forefront of advances in precision medicine by facilitating genomic sequencing, patient education, and connections to expert physicians. We were honored to be able to exhibit at BIO and advocate for rare diseases to such a large and diverse audience.